Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

• Main Authors: Wu Y., Saijo N., Thongprasert S., Yang J., Han B., Margono B., Chewaskulyong B., Sunpaweravong P., Ohe Y., Ichinose Y., Mok T., Young H., Haddad V., Rukazenkov Y., Fukuoka M.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85009789298&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40817
• Institution: Chiang Mai University

© 2016 The Authors Objective The Phase III, randomized, open-label IPASS study (NCT00322452) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung cancer (NSCLC) showed that inv...